1. Home
  2. MXCT vs TNYA Comparison

MXCT vs TNYA Comparison

Compare MXCT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

N/A

Current Price

$1.10

Market Cap

136.2M

Sector

Health Care

ML Signal

N/A

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

N/A

Current Price

$0.57

Market Cap

153.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MXCT
TNYA
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.2M
153.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MXCT
TNYA
Price
$1.10
$0.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
6
Target Price
★ $4.11
$3.20
AVG Volume (30 Days)
325.0K
★ 2.2M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.96
EPS
★ N/A
N/A
Revenue
★ $33,026,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.24
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.64
$0.53
52 Week High
$1.86
$2.35

Technical Indicators

Market Signals
Indicator
MXCT
TNYA
Relative Strength Index (RSI) 41.47 34.06
Support Level $1.11 $0.53
Resistance Level $1.16 $0.81
Average True Range (ATR) 0.05 0.03
MACD -0.01 -0.00
Stochastic Oscillator 15.38 18.50

Price Performance

Historical Comparison
MXCT
TNYA

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Share on Social Networks: